Briefing
Addition of Metastasis-Directed Therapy to Standard of Care for Oligometastatic Disease: Primary Aggregated Analysis of All Baskets from the Phase II Randomized EXTEND Trial
In the multicenter randomized phase 2 EXTEND basket trial, adding metastasis-directed therapy to standard of care improved PFS (HR 0.54, 95% CI 0.41–0.72, P<.001) after a median follow-up of 53 months; exploratorily, detectable ctDNA at enrollment correlated with shorter PFS and survival, and ctDNA clearance at 3 months correlated with improved survival.
- Design: Evidence level 2
- Assay: Not named in the abstract